The Ohio Board of Pharmacy recently revoked the licenses of four Ohio medical spas, with concerns over the sourcing and ...

Explore Hims & Hers' impressive Q1 2025 growth with 111% revenue increase, strategic partnerships, and innovative healthcare solutions.

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

Mass Gen's Dr. Ali Raja explains why some were sent to the emergency room after using semaglutide injections. Raja says some of the symptoms people experienced won't require an ER visit. Raja says not ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

Last year, more than 16 million people googled 'semaglutide' - sold under the brand names Wegovy and Ozempic - as demand for ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a North American, fully integrated, mobile clinical network ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.